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Abstract One of the most common hallmarks of cancer
cells is aneuploidy or an abnormal number of chromo-
somes. This abnormal chromosome content is a conse-
quence of chromosome missegregation during mitosis, a
defect that is seen more frequently in tumor cell divisions as
in normal cell divisions. In fact, a large fraction of human
tumors display a chromosome instable phenotype, meaning
that they very frequently missegregate chromosomes. This
can cause variegated aneuploidy within the tumor tissue. It
has been argued that this hallmark of cancer could be
exploited in anti-cancer therapies. Here we test this
hypothesis by inactivation of the mitotic checkpoint
through RNAi-mediated depletion of an essential check-
point component, Mps1. The mitotic checkpoint delays
segregation of chromosomes during mitosis until all
chromosomes are properly attached to the mitotic spindle.
Its inactivation will therefore lead to increased segregation
errors. Indeed, we show that this can lead to increased cell
death in tumor cells. We demonstrate that increased cell
death is associated with a dramatic increase in segregation
errors. This suggests that inhibition of the mitotic check-
point might represent a useful anti-cancer strategy.
Keywords Aneuploidy.Chromosomal instability.Mps1
Introduction
Chromosomal instability (CIN) is a common characteristic
of solid tumors that is manifested as gains or losses of
whole chromosomes during cell division, leading to
aneuploidy [1]. This propensity of tumor cells was
recognized more than 100 years ago [2], leading to the
hypothesis that CIN could be a driving force in tumorigen-
esis [3]. Indeed, several lines of evidence have since
suggested a causal role for CIN in tumor formation
(reviewed in [4]). However, the exact cause of CIN in
tumors has remained largely unknown.
It has become clear that a broad range of mutations in
different cellular processes can result in CIN [5]. Defects in
mitotic checkpoint function have also been invoked as a
causal event for CIN [5]. The mitotic checkpoint ensures
the fidelity of sister chromatid segregation over the two
daughter cells by inhibiting progression to anaphase until
all chromosome pairs are bi-oriented on the mitotic spindle
(reviewed in [6]). In various human cancers, mitotic
checkpoint function is partially compromised, and altered
expression or mutations of mitotic checkpoint genes have
been shown to be related to CIN and aneuploidy (reviewed
in [5, 7]). Nevertheless, no evidence for checkpoint
malfunctions as a direct cause of CIN in tumor cells has
been found [8–10]. Moreover, the mitotic checkpoint
defects that have been reported (reviewed in [5]) may be
well tolerated by the tumor cell population and most likely
do not result in complete checkpoint inactivation. Complete
inactivation of the mitotic checkpoint, however, results in
gross chromosomal missegregation and is not compatible
with cell viability [11–14]. This has led to the suggestion
that inhibition of the mitotic checkpoint could have
therapeutic potential in cancer treatment [7]. Moreover,
tumor cells that have acquired a decreased checkpoint
activity could be more sensitive to mitotic checkpoint
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cells (reviewed in [7]).
Here, we have explored the relationship between chromo-
some missegregations and tumor cell death by using condi-
tional depletion of the mitotic checkpoint component Mps1.
Materials and Methods
Tissue Culture, Transfections, and Treatments
LS174Tcells were grown in DMEM (Lonza) with 10% Tet-
approved FCS (Clontech), supplemented with pen/strep
(Invitrogen) and ultraglutamine (Lonza). Taxol, MG132,
and doxycycline (used at 1 μg/ml) were from Sigma.
LS174T cells expressing TetR were infected with retrovirus
carrying pSuperior-retro-puro-Mps1 and selected with
2 μg/ml of puromycin. Single colonies were selected after
replating 1–2 cells/well.
Immunofluorescence Microscopy
Cells plated on 12-mm coverslips were harvested after 90-
min MG132 treatment. Fixation was done using 4% PFA in
PEM buffer. CREST was incubated O/N in PBS 3% BSA.
Anti-human Alexafluor647 and DAPI were incubated in
PBS 0.1% Tween. Stained coverslips were mounted with
Vectashield Mounting Medium (Vector). Images were
acquired on a Zeiss 510 Meta confocal laser scanning
microscope with a 63×/1.4NA Plan-ApoChromat objective
using the Zeiss LSM software.
Chromosome Spreads
Nocodazole was added for 4 h to the medium to enrich for
mitotic cells. Cells were treated with 0.075 M KCl at 37°C
for 10 min, centrifuged at 2,000 rpm, and fixed for 20 min
with methanol/acetic acid (3:1). Fixation procedure was
repeated three times. Samples were collected in methanol
and DAPI to stain for DNA. Chromosome spreads were
created by allowing the drops to fall from 30 cm height
onto glass slides. Images were acquired as described above
for immunofluorescence.
Flow Cytometry
Flow cytometry samples were harvested and fixed using
70% ethanol. α-MPM2 was incubated for 1 h in PBS–2%
BSA–0.1% Tween and α-Mouse Cy5 for 1 h in PBS–0.1%
Tween. Stained cells were collected in PBS containing
RNAse and propidium iodide. Fluorescence was measured
on the FACSCalibur and analyzed with Cell Quest Pro
software (BD Biosciences).
Immunoblotting and Antibodies
Cells were lysed in Laemmli buffer. Samples were
separated by SDS–PAGE and transferred to PVDF (Immo-
bilin FL; Millipore). The membranes were cut in half and
blotted with anti-Mps1 and anti-α-tubulin. The following
antibodies have been used for western blot, immunofluo-
rescence, and FACS analysis: Mps1 (Upstate), α-tubulin
(Sigma), CREST (Cortex Biochem), MPM2 (Upstate), anti-
human Alexafluor647, and anti-mouse cy-5 (Jackson)
Colony Formation Assays
Cells (±50,000/well) were plated on six-well plates (Co-
star). Doxycycline was added at day 0 to allow knockdown
of the proteins. At day 11, plates were washed with PBS,
fixed 5 min with 96% methanol, and stained with 0.1%
crystal violet.
Results and Discussion
Efficient Mps1 Depletion Severely Compromises Viability
of Tumor Cells
We have previously shown that absence of Mad2, BubR1,
or Mps1 causes cell death within six cell divisions [14–17].
To examine the effect of conditional inactivation of Mps1
in a mitotic checkpoint proficient cell line, we stably
introduced a doxycycline-inducible vector encoding a small
hairpin RNA (shRNA) directed against human Mps1 in
LS174-T colon carcinoma cells. In addition, this line stably
expresses a tet-repressor such that the addition of tetracy-
cline or doxycycline to the culture medium induces the
expression of the Mps1 shRNA and a consequent depletion
of the endogenous Mps1 protein [15]. A clone was selected
in which expression of Mps1 was reduced by more than
90% upon addition of doxycycline to the culture medium
(Fig. 1a). This degree of depletion of Mps1 severely
compromised the viability of the LS174-T cells since no
colonies grew out in the presence of doxycycline (Fig. 1a).
Thus, selective inhibition of Mps1 compromises the
viability of LS174-T tumor cells.
Mps1 Depletion Inactivates the Spindle Checkpoint
Mps1 is an essential component of the spindle checkpoint,
and its inactivation has been shown to override the cellular
response to spindle poisons such as nocodazole and taxol
[18, 19]. Therefore, we next tested if RNAi-mediated
depletion of Mps1 in the LS174-T cells conditionally
expressing the Mps1 shRNA leads to functional inactiva-
tion of Mps1. To this end, we cultured these cells in the
114 HORM CANC (2011) 2:113–116presence or absence of doxycycline for a period of 3 days
and added 1 μM taxol to the culture medium for the last
18 h of the incubation period. Taxol stabilizes microtubules
and perturbs proper spindle assembly. This will normally
lead to a mitotic delay and an accumulation of cells in
mitosis that is dependent on the mitotic checkpoint. Indeed,
in LS174-T cells that are grown in the absence of
doxycycline, we find a clear accumulation of cells in
mitosis of up to 75% of all cells (Fig. 1b). In contrast,
depletion of Mps1 by the addition of doxycycline leads to
clear inactivation of the mitotic checkpoint since less than
5% of the cells are mitotic in these cultures (Fig. 1b).
Addition of doxycycline to the parental LS174 cells did not
result in a checkpoint override, indicating that this effect
was due to specific depletion of Mps1 (data not shown).
These results indicate that conditional depletion of Mps1
from LS174-T tumor cells leads to inactivation of the
mitotic checkpoint and a concomitant reduction in cell
viability.
Mps1 Depletion Causes Severe Chromosome Alignment
Defects and Enhanced Aneuploidy
Inactivation of Mps1 is expected to compromise a cell’s
ability to achieve proper chromosome alignment on the
mitotic spindle [17]. Therefore, we analyzed if conditional
depletion of Mps1 compromised the fidelity of chromo-
some alignment in LS174-T tumor cells. To this end,
LS174-T cells grown in the presence or absence of
doxycycline for 3 days were incubated with the proteasome
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Fig. 1 Conditional inactivation of Mps1 causes inactivation of the
mitotic checkpoint and tumor cell death. a Left LS174T-TetRMps1,
treated without (−) and with (+) doxycycline (dox) for 3 days, were
immunoblotted for Mps1 and α-tubulin. Right colony formations of
LS174T-TetRMps1 cells treated with and without dox for 11 days. b
FACS analysis of LS174T-TetRMps1 cells treated with or without dox
for 3 days and 1 μM taxol for 18 h. The percentage of mitotic cells
was measured as the fraction of cells with 4N DNA content that were
positive for MPM2
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Fig. 2 Conditional inactivation of Mps1 causes severe defects in
chromosome segregation and severe aneuploidy. a LS174T-TetRMps1
cells were treated with or without dox for 3 days and fixed after
90 min of MG132 treatment. No alignment defects, mild alignment
defects,o rsevere alignment defects indicate mitotic cells with zero,
one to five, or more than five chromosomes not aligned on the
metaphase plate, respectively. b Chromosome spreads were performed
on cells after 4 days of treatment with or without dox. At least 60
chromosome spreads were counted per condition
HORM CANC (2011) 2:113–116 115inhibitor MG132 for 90 min to arrest cells at the metaphase-
to-anaphasetransition.Incontrolcellsgrownintheabsenceof
doxycycline, we found that 90% of all mitotic cells had fully
aligned their chromosomes (Fig. 2a). In contrast, depletion of
Mps1 by the addition of doxycycline to the culture medium
resulted in a severe reduction, as less than 25% of the cells
managed to align their chromosomes in this time (Fig. 2a).
This increase in segregation errors coincides with a more
severe aneuploidy, as evidenced by the karyotyping shown
in Fig. 2b. Taken together, these data show that conditional
inactivation of Mps1 compromises the mitotic checkpoint
and results in a severe defect in chromosome alignment. The
combination of these two effects results in enhanced
segregation errors and as a consequence the karyotype of
the tumor cells becomes highly unstable.
Taken together, our data demonstrate that conditional
inactivation of Mps1 inactivates the mitotic checkpoint,
increases chromosome alignment defects, and compromises
cell viability in vitro. Our data show that inactivation of
Mps1 can inhibit tumor growth and suggest that targeting
Mps1 function might be a useful anti-cancer strategy. Future
studies will have to resolve if partial inhibition of Mps1 can
perturb chromosome segregation in vivo and whether this is
a useful strategy to interfere with tumor growth in vivo. For
this purpose, we would like to develop pharmacological
inhibitors of Mps1 and intend to perform intravital imaging
of cell division of xenografted tumor cells in the mice. These
studies will show if inhibition of Mps1 induces gross
chromosome missegregation in vivo and whether this is
associated with tumor-selective cell death.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabil-
ities in human cancers. Nature 396(6712):643
2. von Hansemann DP (1890) Über asymmetrische Zelltheilung in
Epithelkrebsen und deren biologische Bedeutung. Arch Pathol
Anat Physiol Klin Med 779:299
3. Boveri Theodor (1914) Zur Frage der Entstehung maligner
Tumoren vol. 1
4. Suijkerbuijk SJ, Kops GJ (2008) Preventing aneuploidy: the
contribution of mitotic checkpoint proteins. Biochim Biophys
Acta 1786:24–31
5. Weaver BA, Cleveland DW (2006) Does aneuploidy cause
cancer? Curr Opin Cell Biol 18(6):658
6. Musacchio A, Salmon ED (2007) The spindle-assembly check-
point in space and time. Nat Rev Mol Cell Biol 8(5):379
7. Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer:
aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5(10):773
8. Gascoigne KE, Taylor SS (2008) Cancer cells display profound
intra- and interline variation following prolonged exposure to
antimitotic drugs. Cancer Cell 14:111–122
9. Thompson SL, Compton DA (2008) Examining the link between
chromosomal instability and aneuploidy in human cells. J Cell
Biol 180(4):665
10. Tighe A, Johnson VL, Albertella M, Taylor SS (2001) Aneuploid
colon cancer cells have a robust spindle checkpoint. EMBO Rep 2
(7):609
11. Dobles M et al (2000) Chromosome missegregation and apoptosis
in mice lacking the mitotic checkpoint protein Mad2. Cell 101
(6):635
12. Kalitsis P, Earle E, Fowler KJ, Choo KH (2000) Bub3 gene
disruption in mice reveals essential mitotic spindle checkpoint
function during early embryogenesis. Genes Dev 14(18):2277
13. Michel L et al (2004) Complete loss of the tumor suppressor
MAD2 causes premature cyclin B degradation and mitotic
failure in human somatic cells. Proc Natl Acad Sci USA 101
(13):4459
14. Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human
cancer cells through massive chromosome loss by inhibition
of the mitotic checkpoint. Proc Natl Acad Sci USA 101
(23):8699
15. Janssen A, Kops GJPL, Medema RH (2009) Elevating the
frequency of chromosome missegregation as a strategy to kill
tumor cells. PNAS 106:19108–19113
16. Jelluma N et al (2008) Chromosomal instability by inefficient
Mps1 auto-activation due to a weakened mitotic checkpoint and
lagging chromosomes. PLoS ONE 3(6):e2415
17. Jelluma N et al (2008) Mps1 phosphorylates Borealin to control
Aurora B activity and chromosome alignment. Cell 132(2):233
18. Abrieu A et al (2001) Mps1 is a kinetochore-associated kinase
essential for the vertebrate mitotic checkpoint. Cell 106(1):83
19. Stucke VM, Sillje HH, Arnaud L, Nigg EA (2002) Human Mps1
kinase is required for the spindle assembly checkpoint but not for
centrosome duplication. EMBO J 21(7):1723
116 HORM CANC (2011) 2:113–116